Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRBP 
Corbus Pharmaceuticals Holding (CRBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: CRBP (2-star) is a SELL. SELL since 2 days. Simulated Profits (92.90%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $43.22
1 Year Target Price $43.22
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 974.53% | Avg. Invested days 53 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 206.87M USD | Price to earnings Ratio - | 1Y Target Price 43.22 |
Price to earnings Ratio - | 1Y Target Price 43.22 | ||
Volume (30-day avg) 10 | Beta 2.85 | 52 Weeks Range 4.64 - 20.77 | Updated Date 10/26/2025 |
52 Weeks Range 4.64 - 20.77 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.76 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.24% | Return on Equity (TTM) -49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45304477 | Price to Sales(TTM) 163.32 |
Enterprise Value 45304477 | Price to Sales(TTM) 163.32 | ||
Enterprise Value to Revenue 8.26 | Enterprise Value to EBITDA 0.17 | Shares Outstanding 12255225 | Shares Floating 7542478 |
Shares Outstanding 12255225 | Shares Floating 7542478 | ||
Percent Insiders 0.7 | Percent Institutions 82.61 |
Upturn AI SWOT
Corbus Pharmaceuticals Holding
Company Overview
History and Background
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory, fibrotic, and metabolic diseases. Founded to target the endocannabinoid system, the company has undergone significant strategic shifts, including a refocus on immunology and targeting new mechanisms. The company was founded in 2009.
Core Business Areas
- Drug Development: Focuses on developing and testing drug candidates for various diseases. Includes clinical trials, research and development activities.
- Commercialization: Aims to commercialize approved drugs. However, as of now (October 2024), they do not have any commercialized drugs.
Leadership and Structure
Corbus Pharmaceuticals Holdings is led by its executive team and governed by its board of directors. Specific details can be found on their investor relations page or company website.
Top Products and Market Share
Key Offerings
- CRB-701: A next generation, peripherally restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be immune-selective, potentially avoiding the CNS side effects seen with first generation CB1 blockers. Currently in pre-clinical development. No market share data available. Competitors include companies developing other treatments for inflammatory and fibrotic diseases via different mechanisms. Note that CRBP is focused on new targets and mechanisms, and not just competitive with other CB1 blockers.
- Lenabasum: Lenabasum was formerly Corbus' lead drug candidate. It was under development for the treatment of systemic sclerosis, cystic fibrosis, and dermatomyositis. Clinical trials for these indications failed to meet primary endpoints, leading to a discontinuation of the Lenabasum program. Competitors include other companies developing treatments for these indications.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and dynamic, with companies constantly innovating and developing new treatments for various diseases. The industry is characterized by high R&D costs, regulatory hurdles, and intellectual property protection. The landscape is heavily influenced by factors like demographic changes, healthcare reforms, and technological advancements.
Positioning
Corbus Pharmaceuticals is trying to position itself to be a leader in treating chronic inflammation and fibrotic diseases through immunological methods by developing novel therapeutics. Due to prior failures, they must gain market confidence.
Total Addressable Market (TAM)
The TAM for inflammatory, fibrotic, and metabolic diseases is substantial, potentially reaching hundreds of billions of dollars globally. Corbus Pharmaceuticals aims to capture a portion of this market through its drug development efforts.
Upturn SWOT Analysis
Strengths
- Novel drug candidates in development
- Experienced management team
- Focus on unmet medical needs
- New immunological methods
Weaknesses
- History of clinical trial failures
- Limited financial resources
- Dependence on successful drug development
- No currently marketed products
Opportunities
- Successful clinical trial outcomes
- Strategic partnerships
- Expansion into new therapeutic areas
- Growing market for chronic diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- ABBV
- GILD
- BMY
- MRK
- VRTX
Competitive Landscape
Corbus faces strong competition from established pharmaceutical companies with greater resources and broader product portfolios. Their success depends on the differentiation and effectiveness of their novel drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was driven by lenabasum's clinical development program. The failure of these programs led to a significant downturn.
Future Projections: Future growth is contingent on the successful development of their new drug candidates and their ability to secure financing. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include a strategic shift towards immunology and the development of CRB-701, a peripherally restricted CB1 inverse agonist. The company is focused on novel targets.
Summary
Corbus Pharmaceuticals is currently a high-risk, high-reward investment. Its prospects rely heavily on the success of its new drug candidates. While the shift toward immunology represents a strategic change, the company must overcome the negative sentiment from previous clinical trial failures. Corbus needs to secure additional funding to continue development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Outlets
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence. Market share data is approximate and based on available information. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corbus Pharmaceuticals Holding
Exchange NASDAQ | Headquaters Norwood, MA, United States | ||
IPO Launch date 2014-11-11 | CEO & Director Dr. Yuval Cohen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.corbuspharma.com |
Full time employees 28 | Website https://www.corbuspharma.com | ||
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.